Search Results - "Gandara, R."

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies by Li, Tianhong, Kung, Hsing-Jien, Mack, Philip C, Gandara, David R

“…Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in…”
Get full text

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice by Aggarwal, Charu, Rolfo, Christian D., Oxnard, Geoffrey R., Gray, Jhanelle E., Sholl, Lynette M., Gandara, David R.

“…Upfront tumour genotyping is now considered an essential step in guiding treatment decision-making in the management of patients with advanced-stage…”
Get full text

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients by Zill, Oliver A, Banks, Kimberly C, Fairclough, Stephen R, Mortimer, Stefanie A, Vowles, James V, Mokhtari, Reza, Gandara, David R, Mack, Philip C, Odegaard, Justin I, Nagy, Rebecca J, Baca, Arthur M, Eltoukhy, Helmy, Chudova, Darya I, Lanman, Richard B, Talasaz, AmirAli

“…Cell-free DNA (cfDNA) sequencing provides a noninvasive method for obtaining actionable genomic information to guide personalized cancer treatment, but the…”
Get full text

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases by Mack, Philip C., Banks, Kimberly C., Espenschied, Carin R., Burich, Rebekah A., Zill, Oliver A., Lee, Christine E., Riess, Jonathan W., Mortimer, Stefanie A., Talasaz, AmirAli, Lanman, Richard B., Gandara, David R.

“…Background Circulating cell‐free tumor DNA (ctDNA)‐based mutation profiling, if sufficiently sensitive and comprehensive, can efficiently identify genomic…”
Get full text

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers by Blakely, Collin M, Watkins, Thomas B K, Wu, Wei, Gini, Beatrice, Chabon, Jacob J, McCoach, Caroline E, McGranahan, Nicholas, Wilson, Gareth A, Birkbak, Nicolai J, Olivas, Victor R, Rotow, Julia, Maynard, Ashley, Wang, Victoria, Gubens, Matthew A, Banks, Kimberly C, Lanman, Richard B, Caulin, Aleah F, St John, John, Cordero, Anibal R, Giannikopoulos, Petros, Simmons, Andrew D, Mack, Philip C, Gandara, David R, Husain, Hatim, Doebele, Robert C, Riess, Jonathan W, Diehn, Maximilian, Swanton, Charles, Bivona, Trever G

“…Analysis of a large cohort of EGFR -mutant lung cancer cell-free DNA samples along with longitudinal samples from a patient with EGFR -mutant lung cancer…”
Get full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial by Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr

“…Summary Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and…”
Get full text

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy by Carbone, David P, Gandara, David R, Antonia, Scott J, Zielinski, Christoph, Paz-Ares, Luis

“…As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for…”
Get more information

Squamous cell lung cancer: from tumor genomics to cancer therapeutics by Gandara, David R, Hammerman, Peter S, Sos, Martin L, Lara, Jr, Primo N, Hirsch, Fred R

“…Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged…”
Get full text

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC by Riess, Jonathan W, Gandara, David R, Frampton, Garrett M, Madison, Russell, Peled, Nir, Bufill, Jose A, Dy, Grace K, Ou, Sai-Hong Ignatius, Stephens, Philip J, McPherson, John D, Lara, Jr, Primo N, Burich, Rebekah A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Mack, Philip C, Schrock, Alexa B

“…EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR…”
Get more information

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial by Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

“…Summary Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of…”
Get full text

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study by HIRSCH, Fred R, VARELLA-GARCIA, Marileila, MCCOY, Jason, WEST, Howard, XAVIER, Ana Carolina, GUMERLOCK, Paul, BUNN, Paul A, FRANKLIN, Wilbur A, CROWLEY, John, GANDARA, David R

“…Bronchioloalveolar carcinoma (BAC) and adenocarcinomas with BAC features seem to be increasing in incidence, particularly in younger, never-smoking women…”
Get full text

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403 by Goldberg, Sarah B, Redman, Mary W, Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E, Horn, Leora, Chen, Everett H, Mashru, Sandeep H, Gettinger, Scott N, Melnick, Mary Ann, Herbst, Roy S, Baumgart, Megan A, Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R

“…The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance…”
Get full text

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 by Herbst, Roy S, Gandara, David R, Hirsch, Fred R, Redman, Mary W, LeBlanc, Michael, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh S, Bradley, Jeffrey D, Sparks, Dana, Zhou, Yang, Miwa, Crystal, Miller, Vincent A, Yelensky, Roman, Li, Yali, Allen, Jeff D, Sigal, Ellen V, Wholley, David, Sigman, Caroline C, Blumenthal, Gideon M, Malik, Shakun, Kelloff, Gary J, Abrams, Jeffrey S, Blanke, Charles D, Papadimitrakopoulou, Vassiliki A

“…The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous…”
Get full text

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023 by KELLY, Karen, CHANSKY, Kari, GASPAR, Laurie E, ALBAIN, Kathy S, JETT, James, UNG, Yee C, LAU, Derick H. M, CROWLEY, John J, GANDARA, David R

“…Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib…”
Get full text

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions by Floc'h, Nicolas, Martin, Matthew J, Riess, Jonathan W, Orme, Jonathan P, Staniszewska, Anna D, Ménard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A, Finlay, M Raymond V, McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Burich, Rebekah A, Keck, James G, Gandara, David R, Mack, Philip C, Cross, Darren A E

“…EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally…”
Get full text

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer by Govindan, Ramaswamy, Mandrekar, Sumithra J, Gerber, David E, Oxnard, Geoffrey R, Dahlberg, Suzanne E, Chaft, Jamie, Malik, Shakun, Mooney, Margaret, Abrams, Jeffrey S, Jänne, Pasi A, Gandara, David R, Ramalingam, Suresh S, Vokes, Everett E

“…The treatment of patients with metastatic non-small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment…”
Get full text

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124 by LARA, Primo N, NATALE, Ronald, CHANSKY, Kari, GANDARA, David R, CROWLEY, John, JOSEFLENZ, Heinz, REDMAN, Mary W, CARLETON, Jane E, JETT, James, LANGER, Corey J, KUEBLER, J. Philip, DAKHIL, Shaker R

“…Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC)…”
Get full text

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016 by Tan, Daniel S W, Yom, Sue S, Tsao, Ming S, Pass, Harvey I, Kelly, Karen, Peled, Nir, Yung, Rex C, Wistuba, Ignacio I, Yatabe, Yasushi, Unger, Michael, Mack, Philip C, Wynes, Murry W, Mitsudomi, Tetsuya, Weder, Walter, Yankelevitz, David, Herbst, Roy S, Gandara, David R, Carbone, David P, Bunn, Jr, Paul A, Mok, Tony S K, Hirsch, Fred R

“…Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer…”
Get more information

Aurora Kinases as Anticancer Drug Targets by Gautschi, Oliver, Heighway, Jim, Mack, Philip C, Purnell, Phillip R, Lara, Jr, Primo N, Gandara, David R

“…The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and…”
Get full text

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer by Ramalingam, Suresh S, Maitland, Michael L, Frankel, Paul, Argiris, Athanassios E, Koczywas, Marianna, Gitlitz, Barbara, Thomas, Sachdev, Espinoza-Delgado, Igor, Vokes, Everett E, Gandara, David R, Belani, Chandra P

“…PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms. It also enhances the…”
Get full text